Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment

Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment

Abstract Background To achieve optimal outcomes, an individual approach is needed in the treatment and care of patients. The potential value of tumor mutational burden (TMB) status and/or programmed cell death ligand 1 (PD-L1) expression as biomarkers to predict which patients are most likely to res...

Full description

Bibliographic Details
Main Authors: Tina Krieger, Isobel Pearson, Judith Bell, Jim Doherty, Paul Robbins
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Diagnostic Pathology
Subjects:
Precision medicine
Biomarkers
Tumor mutational burden
Programmed cell death 1 receptor
Gene expression profiling
Online Access:https://doi.org/10.1186/s13000-020-0927-9

Internet

https://doi.org/10.1186/s13000-020-0927-9

Similar Items